LivaNova (NASDAQ:LIVN) Given “Buy” Rating at Mizuho

LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating reaffirmed by stock analysts at Mizuho in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $75.00 price objective on the stock. Mizuho’s price objective would suggest a potential upside of 34.55% from the stock’s previous close.

A number of other research firms have also commented on LIVN. Needham & Company LLC reissued a “buy” rating and issued a $72.00 price target on shares of LivaNova in a research report on Wednesday, March 20th. Robert W. Baird boosted their target price on shares of LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a research note on Thursday, February 22nd. Finally, Barclays boosted their target price on shares of LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a research note on Monday, February 26th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $64.40.

LivaNova Price Performance

LivaNova stock traded up $1.35 during trading hours on Wednesday, hitting $55.74. 187,289 shares of the company traded hands, compared to its average volume of 622,969. The firm has a market cap of $3.01 billion, a P/E ratio of 174.07 and a beta of 0.89. The company has a quick ratio of 2.51, a current ratio of 2.95 and a debt-to-equity ratio of 0.44. The firm’s 50-day simple moving average is $51.97 and its two-hundred day simple moving average is $50.60. LivaNova has a 1-year low of $41.87 and a 1-year high of $59.86.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.10. The company had revenue of $310.10 million for the quarter, compared to analysts’ expectations of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The business’s revenue was up 12.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.81 EPS. As a group, analysts forecast that LivaNova will post 3.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LivaNova

A number of hedge funds have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. purchased a new stake in LivaNova in the 3rd quarter worth approximately $7,932,000. Kingdon Capital Management L.L.C. bought a new position in LivaNova in the third quarter worth approximately $7,123,000. Barclays PLC raised its position in shares of LivaNova by 15.9% during the 3rd quarter. Barclays PLC now owns 851,870 shares of the company’s stock valued at $45,047,000 after purchasing an additional 116,842 shares during the period. SG Americas Securities LLC purchased a new position in LivaNova during the third quarter valued at $1,672,000. Finally, Ameriprise Financial Inc. grew its stake in shares of LivaNova by 96.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 916,632 shares of the company’s stock worth $48,471,000 after buying an additional 449,136 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.